{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:29:40Z","timestamp":1795044580741,"version":"4.10.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Laboratories"},{"name":"Gilead"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV, HBV and HCV infections continue to represent major health concerns, especially among key at-risk populations such as men who have sex with men (MSM), people who inject drugs (PWIDs), transgender women (TGW) and sex workers (SW). The objective of the ANRS-CUBE study was to evaluate the acceptability of a healthcare, community-based strategy offering a triple rapid HIV-HBV-HCV testing, and HBV vaccination, targeted at three priority groups (MSM, PWIDs and TGW\/SWs), in three community centers, in the Paris area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This longitudinal multicentric non-randomized study included all adult volunteers attending one of the three specialized community centers in Paris, between July 2014 and December 2015. HIV, HBV and HCV status and acceptability of HBV vaccination were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3662, MSM, 80 PWIDs and 72 TGW\/SW were recruited in the three centers respectively. Acceptability of rapid tests was 98.5% in MSM and 14.9% in TGW\/SWs, but could not be estimated in PWIDs since the number of users attending and the number of proposals were not recorded. User acceptability of HBV vaccination was weak, only 17.9% of the eligible MSM (neither vaccinated, nor infected) agreed to receive the first dose, 12.2% two doses, 5.9% had a complete vaccination. User acceptability of HBV vaccination was greater in PWIDs and TGW\/SWs, but decreased for the last doses (66.7 and 53.3% respectively received a first dose, 24.4 and 26.7% a second dose and 6.7 and 0% a third dose). Fifty-three participants (49 MSM and 4 PWIDs) were discovered HIV positive, more than half with a recent infection. All but two HIV positive participants were linked to appropriate care in less than one month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rapid HIV-HCV-HBV screening showed a very high level of acceptability among MSM. Efforts need to be made to improve immediate acceptability for HBV vaccination, especially among MSM, and follow-up doses compliance. Our results show the important role of community centers in reaching targets, often fragile, populations, while also suggesting the need to reinforce on-site human support in terms of testing and vaccination, especially when addressing PWIDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05601-7","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T08:19:15Z","timestamp":1605514755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Acceptability of on-site rapid HIV\/HBV\/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-9825","authenticated-orcid":false,"given":"Ruxandra","family":"Calin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Reydellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Plenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Chauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jauffret-Roustide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Kreplak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaenza Freire","family":"Maresca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Derche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rouzioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Chauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"5601_CR1","unstructured":"Global HIV & AIDS statistics \u2014 2018 fact sheet. http:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 13 Apr 2019."},{"key":"5601_CR2","unstructured":"World Health Organization, World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1. Accessed 13 Apr 2019."},{"key":"5601_CR3","volume-title":"UNAIDS world AIDS day report 2011","author":"Joint United Nations Programme on HIV\/AIDS","year":"2011","unstructured":"Joint United Nations Programme on HIV\/AIDS. UNAIDS world AIDS day report 2011. Geneva: UNAIDS; 2011. http:\/\/search.ebscohost.com\/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=450791. Accessed 13 Oct 2019."},{"key":"5601_CR4","unstructured":"Place_of_point-of-care_tests_pocts_in_hepatitis_b_screening_strategy.pdf. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-05\/dir76\/synthese_place_of_point-of-care_tests_pocts_in_hepatitis_b_screening_strategy.pdf. Accessed 3 May 2020."},{"key":"5601_CR5","doi-asserted-by":"publisher","unstructured":"Hutin YJ, Bulterys M, Hirnschall GO. How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc. 2018;21 Suppl Suppl 2. https:\/\/doi.org\/10.1002\/jia2.25050.","DOI":"10.1002\/jia2.25050"},{"key":"5601_CR6","doi-asserted-by":"publisher","unstructured":"Bain LE, Nkoke C, Noubiap JJN. UNAIDS 90\u201390\u201390 targets to end the AIDS epidemic by 2020 are not realistic: comment on \u201cCan the UNAIDS 90\u201390\u201390 target be achieved? A systematic analysis of national HIV treatment cascades\u201d. BMJ Glob Health. 2017;2. https:\/\/doi.org\/10.1136\/bmjgh-2016-000227.","DOI":"10.1136\/bmjgh-2016-000227"},{"key":"5601_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25100","volume":"21","author":"L Marty","year":"2018","unstructured":"Marty L, Cazein F, Panjo H, Pillonel J, Costagliola D, Supervie V, et al. Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. J Int AIDS Soc. 2018;21:e25100.","journal-title":"J Int AIDS Soc"},{"key":"5601_CR8","unstructured":"Bulletin de sant\u00e9 publique infection \u00e0 VIH. Mars 2019. \/ Tous les num\u00e9ros \/ Bulletin de veille sanitaire \/ Publications et outils \/ Accueil. http:\/\/invs.santepubliquefrance.fr\/Publications-et-outils\/Bulletin-de-veille-sanitaire\/Tous-les-numeros\/Bulletin-de-sante-publique-infection-a-VIH.-Mars-2019. Accessed 13 Apr 2019."},{"key":"5601_CR9","unstructured":"Bulletin de sant\u00e9 publique VIH\/sida. Octobre 2019. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/infections-sexuellement-transmissibles\/vih-sida\/documents\/bulletin-national\/bulletin-de-sante-publique-vih-sida.-octobre-2019. Accessed 13 Oct 2019."},{"key":"5601_CR10","unstructured":"Vaux S, Laporal S, Pioche C, Brouard C, Lot F. H\u00e9patites B et C derni\u00e8res donn\u00e9es \u00e9pidemiologiques. Journ\u00e9e nationale de lutte contre les h\u00e9patites B et C, Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9, Paris, France, 15 mai 2018. https:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/1-presentation_s_vaux.pdf."},{"key":"5601_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.respe.2015.10.003","volume":"64","author":"L Weill-Barillet","year":"2016","unstructured":"Weill-Barillet L, Pillonel J, Semaille C, L\u00e9on L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64:301\u201312.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"5601_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2334-9-113","volume":"9","author":"M Jauffret-Roustide","year":"2009","unstructured":"Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009;9:113.","journal-title":"BMC Infect Dis"},{"key":"5601_CR13","doi-asserted-by":"crossref","unstructured":"Brouard C, Pillonel J, Sogni P, Chollet A, Lazarus JV, Pascal X, et al. Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011\u20132013. Epidemiol Infect. 2017;145:1259\u201369.","DOI":"10.1017\/S0950268816003137"},{"key":"5601_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12879-019-3945-z","volume":"19","author":"S Vaux","year":"2019","unstructured":"Vaux S, Chevaliez S, Saboni L, Sauvage C, Sommen C, Barin F, et al. Prevalence of hepatitis C infection, screening and associated factors among men who have sex with men attending gay venues: a cross-sectional survey (PREVAGAY), France, 2015. BMC Infect Dis. 2019;19:315.","journal-title":"BMC Infect Dis"},{"key":"5601_CR15","first-page":"154","volume-title":"Haute Autorit\u00e9 de sant\u00e9","author":"T Cl\u00e9mence","year":"2016","unstructured":"Cl\u00e9mence T. Haute Autorit\u00e9 de sant\u00e9; 2016. p. 154."},{"key":"5601_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030609","volume":"7","author":"JE Matthews","year":"2012","unstructured":"Matthews JE, Stephenson R, Sullivan PS. Factors associated with self-reported HBV vaccination among HIV-negative MSM participating in an online sexual health survey: a cross-sectional study. PLoS One. 2012;7:e30609.","journal-title":"PLoS One"},{"key":"5601_CR17","doi-asserted-by":"publisher","unstructured":"Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti M-D, et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infect Dis. 2015;2. https:\/\/doi.org\/10.1093\/ofid\/ofv162.","DOI":"10.1093\/ofid\/ofv162"},{"key":"5601_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/liv.13135","volume":"36","author":"J Bottero","year":"2016","unstructured":"Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV. HCV and HIV Liver Int. 2016;36:1442\u20139.","journal-title":"HCV and HIV Liver Int"},{"key":"5601_CR19","unstructured":"Fagard C, Champenois K, Joseph J-P, Riff B, Messaadi N, Lacoste D, et al. Feasibility of joint screening for HIV, HBV and HCV by general practitioners in two French Counties, 2012. Bull Epidemiol Hebd. 2014;21\u201322:395\u2013400."},{"key":"5601_CR20","unstructured":"Picard O, Valin N, Girard P-M. Tests rapides d\u2019orientation et de diagnostic de l\u2019infection par le VIH en CDAG : exp\u00e9rience pilote en France (janvier 2010-janvier 2011). Bulletin Epid\u00e9miologique Hebdomadaire. 2011;42:438\u201341."},{"key":"5601_CR21","doi-asserted-by":"publisher","unstructured":"Champenois K, Le Gall J-M, Jacquemin C, Jean S, Martin C, Rios L, et al. ANRS\u2013COM\u2019TEST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men. BMJ Open. 2012;2. https:\/\/doi.org\/10.1136\/bmjopen-2011-000693.","DOI":"10.1136\/bmjopen-2011-000693"},{"key":"5601_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061225","volume":"8","author":"N Lorente","year":"2013","unstructured":"Lorente N, Preau M, Vernay-Vaisse C, Mora M, Blanche J, Otis J, et al. Expanding access to non-Medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (the ANRS-DRAG study). PLoS One. 2013;8:e61225.","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"5601_CR23","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1086\/655651","volume":"202","author":"MS Cohen","year":"2010","unstructured":"Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202(Suppl 2):S270\u20137.","journal-title":"J Infect Dis"},{"key":"5601_CR24","unstructured":"Article - Bulletin \u00e9pid\u00e9miologique hebdomadaire. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/hepatites-virales\/hepatite-c\/documents\/article\/representations-du-traitement-de-l-hepatite-c-chez-les-usagers-de-drogues.-enquete-invs-anrs-coquelicot-france-2004-2007. Accessed 4 Jan 2020."},{"key":"5601_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005040","volume":"4","author":"NP Pai","year":"2014","unstructured":"Pai NP, Dhurat R, Potter M, Behlim T, Landry G, Vadnais C, et al. Will a quadruple multiplexed point-of-care screening strategy for HIV-related co-infections be feasible and impact detection of new co-infections in at-risk populations? Results from cross-sectional studies. BMJ Open. 2014;4:e005040.","journal-title":"BMJ Open"},{"key":"5601_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00126334-200404150-00009","volume":"35","author":"PS Sullivan","year":"2004","unstructured":"Sullivan PS. Lansky a, drake a, HITS-2000 investigators. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr. 2004;35:511\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5601_CR27","first-page":"12","volume":"108","author":"RO Valdiserri","year":"1993","unstructured":"Valdiserri RO, Moore M, Gerber AR, Campbell CH, Dillon BA, West GR. A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep. 1993;108:12\u20138.","journal-title":"Public Health Rep"},{"key":"5601_CR28","unstructured":"pubmeddev, al TA et. HIV testing in community settings in resource-rich countries: a systematic review of the evidence. - PubMed - NCBI. https:\/\/www-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/pubmed\/?term=thornton+hiv+testing+in+community+settings. Accessed 23 Sep 2019."},{"key":"5601_CR29","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2105\/AJPH.2011.300460","volume":"102","author":"LR Metsch","year":"2012","unstructured":"Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102:1160\u20137.","journal-title":"Am J Public Health"},{"key":"5601_CR30","unstructured":"Transgendered people. https:\/\/www.unaids.org\/en\/keywords\/transgendered-people. Accessed 11 Oct 2019."},{"key":"5601_CR31","unstructured":"R\u00e9\u00e9valuation de la strat\u00e9gie de d\u00e9pistage de l\u2019infection \u00e0 VIH en France. Haute Autorit\u00e9 de Sant\u00e9. https:\/\/www.has-sante.fr\/jcms\/c_2024411\/fr\/reevaluation-de-la-strategie-de-depistage-de-l-infection-a-vih-en-france. Accessed 23 Sep 2019."},{"key":"5601_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s15010-016-0975-y","volume":"45","author":"V Ghisla","year":"2017","unstructured":"Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis. Infection. 2017;45:309\u201321.","journal-title":"Infection."},{"key":"5601_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/sti.2006.021493","volume":"82","author":"J Ghosn","year":"2006","unstructured":"Ghosn J, Deveau C, Goujard C, Garrigue I, Sa\u00efchi N, Galimand J, et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect. 2006;82:458\u201360.","journal-title":"Sex Transm Infect"},{"key":"5601_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s10900-014-9932-9","volume":"39","author":"JP Morano","year":"2014","unstructured":"Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health. 2014;39:922\u201334.","journal-title":"J Community Health"},{"key":"5601_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/1471-2458-14-645","volume":"14","author":"B Hayes","year":"2014","unstructured":"Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, et al. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health. 2014;14:645.","journal-title":"BMC Public Health"},{"key":"5601_CR36","doi-asserted-by":"publisher","first-page":"ofw075","DOI":"10.1093\/ofid\/ofw075","volume":"3","author":"JA Barocas","year":"2016","unstructured":"Barocas JA, Linas BP, Kim AY, Fangman J, Westergaard RP. Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs. Open Forum Infect Dis. 2016;3:ofw075.","journal-title":"Open Forum Infect Dis"},{"key":"5601_CR37","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.drugpo.2015.05.001","volume":"26","author":"JT Coats","year":"2015","unstructured":"Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. Int J Drug Policy. 2015;26:1050\u20135.","journal-title":"Int J Drug Policy"},{"key":"5601_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1017\/S0950268816002934","volume":"145","author":"L Leon","year":"2017","unstructured":"Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017;145:895\u2013907.","journal-title":"Epidemiol Infect"},{"key":"5601_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/cid\/cis694","volume":"55","author":"G Wandeler","year":"2012","unstructured":"Wandeler G, Gsponer T, Bregenzer A, G\u00fcnthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV cohort study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408\u201316.","journal-title":"Clin Infect Dis"},{"key":"5601_CR40","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/add.12125","volume":"108","author":"AS de Vos","year":"2013","unstructured":"de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar MEE. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction. 2013;108:1070\u201381.","journal-title":"Addiction."},{"key":"5601_CR41","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1097\/QAD.0000000000001115","volume":"30","author":"F Cazein","year":"2016","unstructured":"Cazein F, Pillonel J, Barin F, Jauffret-Roustide M. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30:1857\u20138.","journal-title":"AIDS."},{"issue":"3 Suppl 2","key":"5601_CR42","doi-asserted-by":"publisher","first-page":"20799","DOI":"10.7448\/IAS.19.3.20799","volume":"19","author":"A Silva-Santisteban","year":"2016","unstructured":"Silva-Santisteban A, Eng S, de la Iglesia G, Falistocco C, Mazin R. HIV prevention among transgender women in Latin America: implementation, gaps and challenges. J Int AIDS Soc. 2016;19(3 Suppl 2):20799.","journal-title":"J Int AIDS Soc"},{"key":"5601_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1473-3099(12)70315-8","volume":"13","author":"SD Baral","year":"2013","unstructured":"Baral SD, Poteat T, Str\u00f6mdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:214\u201322.","journal-title":"Lancet Infect Dis"},{"key":"5601_CR44","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/1471-2458-14-820","volume":"14","author":"S Bowman","year":"2014","unstructured":"Bowman S, Grau LE, Singer M, Scott G, Heimer R. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health. 2014;14:820.","journal-title":"BMC Public Health"},{"key":"5601_CR45","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.2105\/AJPH.2014.302487","volume":"105","author":"DP Shah","year":"2015","unstructured":"Shah DP, Grimes CZ, Nguyen AT, Lai D, Hwang L-Y. Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. Am J Public Health. 2015;105:e36\u201343.","journal-title":"Am J Public Health"},{"key":"5601_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0140-6736(14)60196-3","volume":"384","author":"T Weaver","year":"2014","unstructured":"Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2014;384:153\u201363.","journal-title":"Lancet."},{"key":"5601_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ypmed.2013.04.013","volume":"57","author":"L Topp","year":"2013","unstructured":"Topp L, Day CA, Wand H, Deacon RM, van Beek I, Haber PS, et al. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med. 2013;57:297\u2013303.","journal-title":"Prev Med"},{"key":"5601_CR48","doi-asserted-by":"publisher","unstructured":"Muyunda B, Musonda P, Mee P, Todd J, Michelo C. Educational Attainment as a Predictor of HIV Testing Uptake Among Women of Child-Bearing Age: Analysis of 2014 Demographic and health survey in Zambia. Front Public Health. 2018:6. https:\/\/doi.org\/10.3389\/fpubh.2018.00192.","DOI":"10.3389\/fpubh.2018.00192"},{"key":"5601_CR49","doi-asserted-by":"publisher","unstructured":"Sambah F, Baatiema L, Appiah F, Ameyaw EK, Budu E, Ahinkorah BO, et al. Educational attainment and HIV testing and counselling service utilisation during antenatal care in Ghana: analysis of demographic and health surveys. PLoS One. 2020;15. https:\/\/doi.org\/10.1371\/journal.pone.0227576.","DOI":"10.1371\/journal.pone.0227576"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05601-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T08:23:07Z","timestamp":1605514987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05601-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5601"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05601-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A French ethical committee approved the study on July 25, 2013 (Comit\u00e9 de Protection des Personnes d\u2019H\u00f4tel-Dieu, Paris, France). The study was registered with the French National Agency for Drug Safety (ANSM) on June 5 2013 under the number 2013-A00840\u201345.Written consent was obtained from all study volunteers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. R Calin received grant fees from Bristol-Myers Squibb and consulting fees from Janssen, MSD and Bristol-Myers Squibb, none related to the ANRS CUBE study.Prof. G. Pialoux has received consulting fees from Gilead, Merck, Nephrotek, ViiVhealtcare, Abbvie, none related to the ANRS CUBE study.Prof. S Pol has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, Roche, MSD, MYR_Pharma, Shionogi, Biotest and Abbvie, and grants from Bristol-Myers Squibb, Gilead, Roche and MSD, none related to the ANRS CUBE study.The other authors declared no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"851"}}